Announcement : World Summit of Antivirals
Subscribe to the Antiviral InteliStrat Database
You need to be a member to get access to the database. Many options are available for subscribing along with subscription rates, as described on the Services page.
Below is a sample of information available upon subscribing to the database. This includes detailed product files that can be visualized by clicking on the product's name appearing in the grid.
Contact us at info@antiviralintelistrat.com for a free TRIAL!
Log into your account
Database Sample
Sponsor(s)  |
Product | Type of product | Mode of action | Viral family | Virus | Status-1 | Status-2 | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Sanofi Pasteur | ChimeriVax- Dengue | Vaccine | Recombinant, viral expr vector | Flaviviridae | Dengue virus | Phase IIa | Evaluated as tetravalent vaccine; Development initiated at Acambis | |||
|
GlaxoSmithKline (GSK) | Retrovir® zidovudine; azidothymidine; AZT; BW A509U; Zydowin |
Inhibitor | NRTI | Retroviridae | HIV (Human Immunodeficiency virus) | Market | Approved for market in US (Mar. 19, 1987) and other markets | |||
|
Pharmacor | P-1946 | Inhibitor | PI | Retroviridae | HIV (Human Immunodeficiency virus) | Preclinical | Lead compound | |||
|
Novartis | Focetria® Fluad-H5N1; Fluad H5N1 |
Vaccine | Non-recombinant protein vaccine | Orthomyxoviridae | Avian Influenza virus | Market | Approved for market in EU (May 2, 2007); See Remarks | |||
|
|||||||||||